Bagsværd, Denmark, 30 April 2018 - In accordance with Section 10 of the Danish Statutory Order on Issuers' Disclosure Obligations, Novo Nordisk is required to publish the total number of voting rights and the size of the share capital in Novo Nordisk A/S as per the end of a month where changes therein have occurred.
Referring to Company Announcement no 34/2018 dated 24 April 2018, please find below a statement regarding the total number of voting rights and share capital in Novo Nordisk A/S as per 30 April 2018.
Further information
| Media: | ||
| Anne Margrethe Hauge | +45 4442 3450 | |
| Ken Inchausti (US) | +1 609 786 8316 | |
| Investors: | ||
| Peter Hugreffe Ankersen | +45 3075 9085 | |
| Anders Mikkelsen | +45 3079 4461 | |
| Christina Kjær | +45 3079 3009 |
Company Announcement no. 35 / 2018
Attachment